Skip to main content
Caplight Logo









Primary Peptides, Inc.

Primary Peptides, Inc.

Private
VancouverHealthcare & Life Scienceshttps://primarypeptides.com/

Last Round

Series A

Feb 1, 2025

Est. Valuation

$75M

Total Funding Raised

$229,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Primary Peptides, Inc. is a biotechnology company that develops novel peptide therapeutics for neurological and cardiovascular diseases using protein manipulation technologies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

peptide therapeuticsbiotech platformneurodegenerative diseasedrug discoveryCNS therapeuticsblood-brain barrierprotein degradationCHAPTACundruggable targetsbiotech licensingprotein-protein interactiondrug pipelinetargeted therapynext-gen biologicsprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Primary Peptides, Inc. Comparables

Compare Primary Peptides, Inc. with similar companies based on industry and business-model similarity.

Primary Peptides, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Argenica Therapeutics
83%
Axoltis Pharma
82%
Infensa Bioscience
79%

Primary Peptides, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 1, 2025
GrantMay 1, 2023
GrantMay 2, 2022

Primary Peptides, Inc. Investors

Notable investors and investment history

Primary Peptides, Inc. investors
InvestorRounds
National Research Council of CanadaGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 413% MoM.

  • May 15, 2026

    Monthly visitors increased 435% MoM.

Primary Peptides, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Primary Peptides, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Primary Peptides, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersVancouver
Employee Range4
Year Founded2013
Last FundingFeb 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?